Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Transfus Apher Sci ; 62(6): 103790, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37640602

ABSTRACT

INTRODUCTION: Most of the blood banks worldwide do not defer donors for their medication, with the exception of the teratogenic and platelet aggregation-inhibiting drugs use. In Serbia, where around 245.000 units of blood are collected each year, it is not common practice to consider the medication of potential blood donors. Therefore, the aim of this study was to quantify the presence of antihypertensive drugs in blood samples collected from blood donors treated for hypertension and to raise the issue of the recipient risks posed by drug residues in blood products. METHODS: Serum samples were obtained from 450 volunteer blood donors collected during the year 2017 who reported the use of antihypertensive drugs. All blood donors were required to interrupt regular antihypertensive therapy for 24 h before blood donation and LCMS determination of antihypertensive drugs was performed. RESULTS: Beta blockers were detected in 81 out of 203 samples which tested positive for the presence of antihypertensive drugs. Concentrations above the limit of quantification were determined in 58% of samples positive on beta blockers, containing metoprolol and bisoprolol in amounts sufficient to produce a therapeutic effect in the recipient. CONCLUSION: Therefore, the obtained results suggested that the safety of blood donation from individuals with treated hypertension should not be neglected. A solution for this problem might be the establishment of a standard LCMS screening procedure as a tool for testing the blood of donors taking drugs.


Subject(s)
Antihypertensive Agents , Hypertension , Humans , Antihypertensive Agents/pharmacology , Antihypertensive Agents/therapeutic use , Blood Donation , Serbia , Blood Donors
2.
Biochim Biophys Acta ; 1840(9): 2702-8, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24915603

ABSTRACT

BACKGROUND: Extracorporeal photopheresis that exposes isolated white blood cells to 8-methoxypsoralen (8-MOP) and ultraviolet-A (UV-A) light is used for the management of cutaneous T-cell lymphoma and graft-versus-host disease. 8-MOP binds to DNA of both tumor and normal cells, thus increasing the risk of carcinogenesis of normal cells; and also kills both tumor and normal cells with no selectivity after UV-A irradiation. Hexaminolevulinate (HAL)-induced protoporphyrin-IX is a potent photosensitizer that localizes at membranous structures outside of the nucleus of a cell. HAL-mediated photodynamic therapy selectively destroys activated/transformed lymphocytes and induces systemic anti-tumor immunity. The aim of the present study was to explore the possibility of using HAL instead of 8-MOP to kill cells after UV-A exposure. METHODS: Human T-cell lymphoma Jurkat and Karpas 299 cell lines were used to evaluate cell photoinactivation after 8-MOP and/or HAL plus UV-A light with cell proliferation and long term survival assays. The mode of cell death was also analyzed by fluorescence microscopy. RESULTS: Cell proliferation was decreased by HAL/UV-A, 8-MOP/UV-A or HAL/8-MOP/UV-A. At sufficient doses, the cells were killed by all the regimens; however, the mode of cell death was dependent on the treatment conditions. 8-MOP/UV-A produced apoptotic death exclusively; whereas both apoptosis and necrosis were induced by HAL/UV-A. CONCLUSION: 8-MOP can be replaced by HAL to inactivate the Jurkat and Karpas 299 T-cell lymphoma cells after UV-A irradiation via apoptosis and necrosis. This finding may have an impact on improved efficacy of photopheresis.


Subject(s)
Aminolevulinic Acid/analogs & derivatives , Lymphoma, T-Cell/drug therapy , Methoxsalen/pharmacology , Photopheresis , Photosensitizing Agents/pharmacology , Aminolevulinic Acid/pharmacology , Cell Proliferation/drug effects , Cell Proliferation/radiation effects , Cell Survival/drug effects , Cell Survival/radiation effects , Humans , Jurkat Cells , Lymphoma, T-Cell/pathology , Ultraviolet Rays
3.
Bone Marrow Transplant ; 46(8): 1118-27, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21057550

ABSTRACT

Photodynamic therapy (PDT) with porphyrin precursors is an established therapy for certain tumors. This study aimed to explore the use of hexaminolevulinate (HAL), a porphyrin precursor, for photodynamic purging of BM grafts contaminated with cells of the 4T1 breast carcinoma cell line. The optimal PDT dose was not effective in eradicating 4T1 cells when the tumor cells were mixed with murine marrow cells in vitro. However, the number of pulmonary metastases was reduced, and the survival of experimental animals was prolonged substantially when they were subjected to TBI followed by transplantation of syngeneic BM containing metastasized 4T1 cells that had been treated ex vivo by HAL-PDT. Despite the failure of in vitro experiments, HAL-based photodynamic purging could be a useful modality for treating animals bearing an experimental breast carcinoma.


Subject(s)
Aminolevulinic Acid/analogs & derivatives , Bone Marrow Purging/methods , Mammary Neoplasms, Experimental/drug therapy , Mammary Neoplasms, Experimental/pathology , Photochemotherapy/methods , Photosensitizing Agents/pharmacology , Aminolevulinic Acid/pharmacokinetics , Aminolevulinic Acid/pharmacology , Animals , Bone Marrow/drug effects , Bone Marrow/pathology , Cell Line, Tumor , Female , Hematopoietic Stem Cell Transplantation/methods , Lung Neoplasms/prevention & control , Lung Neoplasms/secondary , Mice , Mice, Inbred BALB C , Photosensitizing Agents/pharmacokinetics , Protoporphyrins/pharmacokinetics , Protoporphyrins/pharmacology , Tumor Cells, Cultured
4.
Bone Marrow Transplant ; 45(10): 1553-61, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20118993

ABSTRACT

Photodynamic therapy (PDT) with porphyrin precursors has been established for tumor treatment. This study aimed at examining applicability of hexaminolevulinate (HAL) for photodynamic purging of leukemic cells from BM grafts and evaluating the clinical relevance of in vitro models. The PDT dose resulting in no colony formation by leukemic cells in vitro, in pure form or in a mixture with BM cells, was insufficient for complete killing of the leukemic cells ex vivo and for the treatment of the leukemia-bearing animals in vivo. The efficacy of HAL-PDT in cell lines in vitro should be verified in clinically relevant in vivo models.


Subject(s)
Aminolevulinic Acid/analogs & derivatives , Bone Marrow Cells/drug effects , Bone Marrow Purging/methods , Bone Marrow Transplantation , Leukemia L1210/therapy , Photosensitizing Agents/pharmacology , Aminolevulinic Acid/pharmacology , Animals , Bone Marrow Cells/chemistry , Cell Line, Tumor , Cell Survival/drug effects , Female , Gamma Rays , Granulocytes/chemistry , Granulocytes/drug effects , Leukemia L1210/mortality , Mice , Mice, Inbred DBA , Osmolar Concentration , Photochemotherapy , Protoporphyrins/analysis , Survival Analysis , Tumor Stem Cell Assay , Whole-Body Irradiation/mortality
5.
Eur J Drug Metab Pharmacokinet ; 35(1-2): 75-8, 2010 Sep.
Article in English | MEDLINE | ID: mdl-21495270

ABSTRACT

Influence of two newly synthesized bile acids derivates, namely sodium salt of monoketocholic acid MKH-Na and methyl ester of monoketocholic acid MKH-Me on tramadol (12.5 mg/kg oral and intramuscular) analgesic effect was examined in this research. Analgesic effect was measured by antinociceptive hot plate method. Interaction was estimated by detection of changes in analgesic effect of tramadol combined with bile acids (subcutaneous administration of 4 mg/kg 20 min before tramadol) compared to analgesic effect of the same dose of tramadol given alone. Hydrosoluble sodium salt of monoketocholic acid did not show interaction with tramadol, regardless of the route of administration of tramadol. However, methyl ester of monoketocholic acid increased the analgesic effect of tramadol when it was given intramuscularly. After oral administration of tramadol, methyl ester of monoketocholic acid decreased the analgesic effect of tramadol. According to the time point when interaction reached statistically significant difference, it can be presumed that after intramuscular administration of tramadol, methyl ester of monoketocholic acid increases tramadol absorption and transport to brain and in that way increases its analgesic effect. The analgesic effect of tramadol after oral administration was decreased, which could be explained by the induction of tramadol metabolism in the liver, but should be examined in more details.


Subject(s)
Analgesics, Opioid/pharmacology , Cholic Acids/pharmacology , Pain Measurement/drug effects , Tramadol/pharmacology , Administration, Oral , Analgesics, Opioid/administration & dosage , Animals , Injections, Intramuscular , Male , Mice , Mice, Inbred Strains , Tramadol/administration & dosage
6.
Article in English | MEDLINE | ID: mdl-19462923

ABSTRACT

The interaction of diclofenac and ketoprofen, both applied intraperitoneally in a dose of 8 mg/kg for twenty-eight days, was assessed with cardioactive drugs in rats. Interaction was assessed on the basis of ECG records after the infusion of adrenaline, verapamil or lidocaine to the rats treated with diclofenac or ketoprofen vs control. The infusion time was measured in seconds to the moment of the appearance of the first heart reaction to the infusion of the cardioactive drug, then to the appearance of more frequent changes in the ECG record, and finally, to the occurrence of the toxic effect. It was also measured the plasma concentrations of sodium and potassium ions. As well as diclofenac and ketoprofen concentration, 2 hours after single and 28th dose. ECG patterns revealed no occurrence of cardiotoxic action of diclofenac and ketoprofen. The treatment with diclofenac caused significantly lower sodium plasma concentrations whereas the concentration of potassium was increased. Diclofenac concentrations were the same after a single and multiple doses, whereas concentrations of ketoprofen were significantly higher after a single dose than after its multiple applications.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Cardiovascular Agents/pharmacology , Diclofenac/pharmacology , Ketoprofen/pharmacology , Animals , Anti-Arrhythmia Agents/pharmacology , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Calcium Channel Blockers/pharmacology , Cardiovascular Agents/administration & dosage , Diclofenac/administration & dosage , Drug Interactions , Electrocardiography/drug effects , Epinephrine/pharmacology , Heart/drug effects , Infusions, Intravenous , Injections, Intraperitoneal , Ketoprofen/administration & dosage , Lidocaine/pharmacology , Potassium/blood , Rats , Rats, Wistar , Sodium/blood , Vasoconstrictor Agents/pharmacology , Verapamil/pharmacology
7.
Article in English | MEDLINE | ID: mdl-17569242

ABSTRACT

We studied the effect of caffeine on the transport of quinidine through the blood-brain barrier (BBB) to the central nervous system (CNS) in rats. The anesthetized animals received quinidine in the form of a retrograde intra-arterial bolus injection (15 s) into the right axillary artery 30 min after receiving a subcutaneous injection of caffeine (test group) or physiological solution (control group). Rats were decapitated at 30, 60, 90, 120, and 240 s after quinidine administration. Blood samples were taken from the left jugular vein. Upon washing, the brain, was divided into the brainstem, cerebellum, and cerebral hemispheres to determine the quinidine content in each section, using a standard spectrofluorimetric method. Quninidine attained maximal concentrations in the CNS with a latency compared with that in blood; the CNS values were higher. Quinidine kinetics showed two compartments in the CNS, one consisting of the brainstem and cerebellum, in which quinidine concentrations were higher, and the other the cerebral hemispheres. Caffeine caused a significant deceleration of quinidine transition through the BBB to the CNS.


Subject(s)
Blood-Brain Barrier/metabolism , Brain/metabolism , Caffeine/pharmacology , Central Nervous System Stimulants/pharmacology , Quinidine/pharmacokinetics , Animals , Biological Transport, Active , Central Nervous System Stimulants/blood , Central Nervous System Stimulants/pharmacokinetics , Drug Synergism , Female , Injections, Intra-Arterial , Male , Quinidine/blood , Rats , Rats, Wistar
8.
Cytopathology ; 18(2): 87-95, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17397493

ABSTRACT

OBJECTIVES: Urinary bladder urothelial carcinoma is diagnosed by a combination of cystoscopy and biopsy, with cytology as a valuable additional technique. The accuracy of cytological diagnosis depends on the experience of the cytologist and can inevitably vary from one cytologist to another. There is a need for an easy, reliable and objective diagnostic method. In the present study a new method was designed for the detection of bladder cancer cells in urine. METHODS: Flow cytometry was utilized to detect protoporphyrin IX in an artificial model consisting of normal urinary bladder transitional epithelial cells (NBECs) from healthy volunteers' urine and an established human urinary bladder carcinoma cell line, TCCSUP, after incubation with hexaminolevulinate (HAL). In addition, urine samples from 19 patients with histopathologically confirmed superficial bladder cancer were examined. RESULTS: Incubation of NBECs or TCCSUP cells with HAL for 1 hour resulted in production of protoporphyrin IX only in the TCCSUP cells. Incubation of a mixture of NBECs and TCCSUP cells with HAL gave rise to a separated subpopulation of cells with protoporphyrin IX fluorescence. After cell sorting by flow cytometry the protoporphyrin IX-containing subpopulation of cells was confirmed as TCCSUP cells on cytological examination. It was possible to detect 5% TCCSUP cells in the mixture of NBECs/TCCSUP cells. To test the feasibility of the method in clinica diagnosis, urine samples from patients with bladder cancer were also measured with comparable, although preliminary and limited, results to those of cytological examination. CONCLUSIONS: The preliminary results show that the technique may be feasible for the detection of bladder cancer cells in urine with possible advantages of simplicity, reliability and objectivity.


Subject(s)
Aminolevulinic Acid/analogs & derivatives , Carcinoma, Transitional Cell/pathology , Cytodiagnosis/methods , Flow Cytometry/methods , Urinary Bladder Neoplasms/pathology , Urothelium/pathology , Aged , Aged, 80 and over , Aminolevulinic Acid/pharmacology , Aminolevulinic Acid/urine , Biomarkers, Tumor/metabolism , Carcinoma, Transitional Cell/metabolism , Carcinoma, Transitional Cell/urine , Cell Line, Tumor , Feasibility Studies , Female , Humans , Male , Middle Aged , Protoporphyrins/metabolism , Reproducibility of Results , Sensitivity and Specificity , Urinalysis , Urinary Bladder Neoplasms/metabolism , Urinary Bladder Neoplasms/urine , Urine/cytology , Urothelium/drug effects , Urothelium/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...